Skip to content
Clinical Trials – home

Chamomile Extract for Irritable Bowel Syndrome: A Comprehensive Guide

2 / 2
trials open to patients / all trials
1+
Countries

In short

This article discusses clinical trials investigating the use of a drug containing dry extract from chamomile flower, along with myrrh and coffee charcoal, for treating irritable bowel syndrome (IBS). The trials focus on patients with diarrhea-predominant IBS (IBS-D) and mixed-type IBS (IBS-M), evaluating the drug's efficacy, safety, and tolerability compared to a placebo.

At a glance

Drug Name
MYRRHINIL-INTEST®
Active Ingredients
Myrrh, Coffee Charcoal, Dry Extract from Chamomile Flower
Conditions Studied
Diarrhea-predominant IBS (IBS-D), Mixed-type IBS (IBS-M)
Primary Endpoints
Reduction in abdominal pain, improvement in stool consistency (IBS-D), overall bowel health improvement (IBS-M)
Key Inclusion Criteria
Age 18-75, confirmed IBS-D or IBS-M diagnosis, specific symptom requirements
Key Exclusion Criteria
Other gastrointestinal diseases, recent antibiotic use, pregnancy/breastfeeding
Assessment Tools
NRS Pain, Bristol Stool Form Scale, IBS-SSS, IBS-QoL, PGI-I
Treatment Duration
Up to 8 weeks

What is Chamomile Extract?

Chamomile extract is a natural substance derived from chamomile flowers. In the context of this article, we're focusing on a specific formulation called "DRY EXTRACT FROM CHAMOMILE FLOWER (4-6:1): EXTRACTION SOLVENT: ETHANOL 60% (M/M)". This extract is one of the active ingredients in a medication called MYRRHINIL-INTEST®, which also contains myrrh and coffee charcoal.

Medical Uses

MYRRHINIL-INTEST®, which contains chamomile extract, is primarily used to treat Irritable Bowel Syndrome (IBS), particularly the diarrhea-predominant (IBS-D) and mixed (IBS-M) subtypes. IBS is a common digestive disorder characterized by abdominal pain, bloating, and changes in bowel habits.

Specifically, this medication is being studied for its effectiveness in:

  • Reducing abdominal pain associated with IBS
  • Improving stool consistency in patients with diarrhea-predominant IBS
  • Enhancing overall bowel health in patients with mixed-type IBS

How It Works

While the exact mechanism of action is not fully understood, chamomile extract is believed to have several beneficial properties:

  • Anti-inflammatory effects: Chamomile may help reduce inflammation in the digestive tract.
  • Antispasmodic properties: It may help relax the smooth muscles of the intestines, potentially reducing cramping and pain.
  • Calming effects: Chamomile is known for its mild sedative properties, which might help reduce stress-related digestive symptoms.

The combination with myrrh and coffee charcoal in MYRRHINIL-INTEST® is thought to provide a synergistic effect in managing IBS symptoms.

Clinical Trials

Two clinical trials are currently investigating the efficacy and safety of MYRRHINIL-INTEST® for IBS:

  1. A study focusing on patients with diarrhea-predominant IBS (IBS-D).
  2. A study including both diarrhea-predominant (IBS-D) and mixed-type IBS (IBS-M) patients.

These trials aim to assess:

  • The medication's effectiveness in reducing abdominal pain
  • Improvements in stool consistency and frequency
  • Overall changes in IBS symptoms and quality of life
  • The safety and tolerability of the medication

Dosage and Administration

MYRRHINIL-INTEST® is typically administered as coated tablets. In the clinical trials, the maximum daily dose is 12 tablets, with a total treatment period of up to 8 weeks. However, the exact dosage may vary depending on individual patient needs and should be determined by a healthcare professional.

Potential Side Effects

While the full safety profile is still being investigated in the clinical trials, potential side effects may include:

  • Allergic reactions, especially in people with known sensitivities to chamomile or related plants
  • Gastrointestinal discomfort
  • Interactions with other medications

It's important to note that the clinical trials are designed to carefully monitor and assess any adverse events that may occur during treatment.

Precautions and Contraindications

Based on the clinical trial exclusion criteria, MYRRHINIL-INTEST® may not be suitable for:

  • Patients with inflammatory bowel diseases like ulcerative colitis or Crohn's disease
  • Individuals with known hypersensitivity to chamomile, myrrh, or coffee charcoal
  • Patients with certain liver or kidney dysfunctions
  • Pregnant or breastfeeding women
  • Patients with certain other medical conditions or taking specific medications

Always consult with a healthcare professional before starting any new medication, including herbal supplements like chamomile extract.

Questions people often ask

Conditions where Dry Extract From Chamomile Flower (4-6:1): Extraction Solvent: Ethanol 60% (M/M) is being studied

Each condition opens its own overview and trial list

Trials with Dry Extract From Chamomile Flower (4-6:1): Extraction Solvent: Ethanol 60% (M/M)

Recruiting trials first

See all 2 →
Quick filters
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.